About APL

We are one of Europe’s largest manufacturers of extemporaneous medicines and a leading contract manufacturer within Life Science

Our operation

Our task is to develop and manufacture individually adapted medicines for patients with special needs, such as children who need specific strengths or flavours, and persons suffering from various over-sensitivities. The operation is carried out in dialogue and close collaboration with specialists, county councils and public agencies, to ensure that patients get access to the correct treatment.

APL also carries out development and contract manufacture of medicines on behalf of biotechnology and pharmaceutical companies. We also have resources to develop, manufacture and analyse products such as specialist medicines and other niche products.

Our history

The Swedish pharmacy sector was nationalised in the early 1970s, and Apoteksbolaget AB was formed. This company included Apotek Produktion & Laboratorium AB (APL), which was tasked to provide prescribers and therefore patients with extemporaneous medicines, or specially manufactured preparations for individually adapted treatment. In conjunction with the deregulation of the pharmacy market in 2009, it was no longer permissible for pharmacies to produce medicines simultaneously, and therefore APL was disconnected from Apoteket AB in June 2010.

Tillverkning Malmö

Vision, mission and goals

Our vision

We make a difference for patients with special needs

Our mission

We develop and manufacture extemporaneous and orphan drugs as part of a social mission and on behalf of other pharmaceutical companies, to create the greatest possible patient benefit.

Our goals

  • We aim to be a sustainable and efficient supplier of extemporaneous drugs and stock preparations
  • We aim to be competitive and profitable in CDMO
  • We aim to be an attractive employer by attracting, developing and retaining the right employees

When a life is at stake, every minute counts

View an intensive and carefully controlled process in sterile manufacturing at APL.

Sustainable development

We constantly analyse our activities, products and services in order to identify improvement measures within quality, environment and in the social sphere.


Work for us

We need more skilled, solution-oriented and responsible empolyees and we can offer opportunities for development in an exciting industry.


 

APL in figures

1 509 mkr

Net turnover

2 000

Extemporaneous medicines

506

Number of employees

Our units

Our production units are located in Stockholm, Göteborg, Malmö and Umeå.

Certificates

We are certified in relation to medical devices, environment and work environment.

Orderläggning

Extemporeläkemedel och lagerberedningar

Beställ online via EbEx

Kundservice

Telefon: 010-447 97 00
e-post: kundservice@apl.se

 

Öppettider:
Helgfria vardagar 08:00-17:00

Reservrutin

Reservrutinen används endast för akuta medicinskt viktiga beställningar av extemporeläkemedel under tiden EbEx ordersystem inte kan nås. För att kunna använda dig av rutinen så krävs det att du redan är befintlig kund hos APL och har ett kundnummer.

Beställningar görs på för ändamålet avsedd blankett och får inte innehålla några patientuppgifter.

Beställningen skickas via e-post till kundservice@apl.se.


 

Contact

Visiting adress:

Prismavägen 2, Kungens Kurva


+46 10 447 96 00


Other contact information

About APL

Apotek Produktion & Laboratorier (APL) is one of Europe’s leading companies manufacturing extemporaneous drugs and stock preparations. We have a social mission from the Swedish government, but also work together with other pharmaceutical companies to create the greatest possible patient benefit. Our vision is that we will make a difference for patients with special needs. We are also an established contract manufacturer within Life Science in Scandinavia, where we deliver services within development and analysis. With more than 500 employees and five manufacturing units in Malmö, Gothenburg, Stockholm and Umeå, we develop drugs that improve and save lives.


Read more